Beiersdorf, the company behind NIVEA, Eucerin, and La Prairie, has launched a second-generation corporate venture capital fund with a €100 million commitment – doubling the size of the fund it launched in 2020. Beiersdorf Venture Capital invests globally from early to growth stage, with initial investments typically ranging from €0.5 million to €5 million.
The fund focuses on companies at the intersection of skin care and four thesis areas: life sciences and biotechnology, sustainability, AI-enabled technologies, and digital health solutions. Since 2020, Beiersdorf Venture Capital has built a portfolio of more than 15 companies, including S-Biomedic (skin microbiome science, eventually acquired by Beiersdorf), Vincere Biosciences (mitophagy/longevity), and Turbine (AI-based cell simulation).
“With our second, €100 million venture capital fund, we build on the conviction that pioneering ideas need both capital and the right partners,” said Ascan Voswinckel, head of Beiersdorf Venture Capital. “In addition to funding, we provide access to Beiersdorf’s leading R&D expertise and global brand platforms, a combination that creates sustainable value for both sides.”
For women’s health-adjacent startups working on skin microbiome, hormonal skin changes, or dermatological conditions linked to menopause, PCOS, or pregnancy, Beiersdorf’s scale and distribution could be a meaningful strategic partner – and €100 million in committed capital signals serious intent to acquire and integrate external innovation.
